



Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

**Cais Rhyddid Gwybodaeth / Freedom of Information request**  
**Ein Cyf / Our Ref: 23-D-051**

Please note that we have provided this information for the period December 2022 to February 2023.

**You asked:**

**Question 1**

**How many patients has your Organisations treated in the past 3 months for Chronic Lymphocytic Leukaemia (CLL)? In case you do not treat CLL, which other Organisation do you refer patients needing treatment to?**

I can confirm SBUHB do treat patients with CLL. We have provided the number of SBUHB admissions, between 01/12/22 and 29/02/23, inclusive, with an admitting diagnosis of Chronic Lymphocytic Leukaemia.

6 patients were admitted 11 times in the time period.

**Question 2**

**How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months with the following:**

BR (bendamustine + rituximab)	0
Calquence (acalabrutinib)	7
FCR (fludarabine + cyclophosphamide + rituximab)	0
Gazyva (obinutuzumab) + chlorambucil	<5*
Imbruvica (ibrutinib)	7
Venclexta (venetoclax)	5
Venclexta (venetoclax) + Gazyva (obinutuzumab)	<5*
Venclexta (venetoclax) + rituximab	<5*
Zydelig (idelalisib) + rituximab	0
Any other systemic anti-cancer therapy	0
Wait and watch (no active treatment)	**



### Question 3

**If your Organisation does treat Chronic Lymphocytic Leukaemia patients, do you currently participate in any ongoing clinical trials for the treatment of CLL? If so, can you please provide the name of each trial along with the number of patients taking part?**

In the time period specified, SBUHB were taking part in three clinical studies;

- FLAIR - Front-Line therapy in CLL: Assessment of Ibrutinib-containing Regimes
- LOXO 20020 - A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-321)
- LOXO 20030 - A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)

24 patients recruited in total across all trials.

\* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

\*\* To obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act and The Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulation 2004 provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

